Accelerated Partial Breast Irradiation (APBI) with Balloon Brachytherapy
Hologic’s targeted radiation therapy is a breakthrough early-stage breast cancer treatment that can offer an alternative to whole breast radiation or a mastectomy.
Balloon brachytherapy solutions directly target the lumpectomy cavity, where the cancer is most likely to recur, sparing healthy tissues and organs from the damaging effects of radiation.1-2
Hologic offers a choice between two systems: MammoSite® and Contura® systems.
MammoSite Targeted Radiation Therapy Solutions
The MammoSite system is Hologic’s legacy balloon brachytherapy system. It’s available in two configurations: single-lumen and multi-lumen catheters. The multi-lumen catheter has four offset lumens to allow for dosimetric optimization to minimize skin dose. This balloon also has a purple keyed stylet that helps you position the balloon after implantation.
Contura Multi-lumen Balloon Solutions
Contura multi-lumen balloon is a single insertion balloon brachytherapy applicator available in two sizes and two shaft configurations (standard and FLEX). With five treatment lumens, you can shift the isodose curve from the chest wall. There are two vacuum ports on the proximal and distal ends of the balloon that allow you to remove fluid or air to facilitate tissue conformance to the balloon.
Both MammoSite and Contura multi-lumen balloon brachytherapy applicators are the only single-insertion APBI technologies that meet or exceed all B-39 dosimetric guidelines.
As such, they allow you to easily satisfy the current clinical recommendation that the dose to the skin be maintained to less than 125% of the prescription dose.3-5
Clinical Data
With seven years of positive clinical evidence, and over 90,000 women successfully treated, you can feel confident recommending this solution to your patients.2,6,8
The final analysis of the American Society of Breast Surgeons (ASBS) MammoSite Breast Brachytherapy Registry Trial (N=1440) confirmed the excellent results of treatment efficacy, cosmesis and toxicity. The study also concluded that these results are similar and compared favorably with other forms of APBI and whole breast irradiation with similar follow-up period.2
- Excellent/good cosmesis was observed in:
91.3% of patients at 5 years.
90.5% of patients at 6 years.
90.6% of patients at 7 years.
- Overall rate of fat necrosis was 2.5% with an infection rate of 9.6% and few late toxicity events beyond 2 years.
- Overall symptomatic seroma rate was 13.4% and 0.6% beyond 2 years.
- Ipsilateral breast tumor recurrence (IBTR) was developed in 41 cases (2.8%) for a 5-year actuarial rate of 3.8 % (3.7% for IBC and 4.1% for DCIS).
The Five-year Results of the Initial Clinical Trial of MammoSite Balloon Brachytherapy for Partial Breast Irradiation in Early-Stage Breast Cancer involving 43 patients7 shows:
- No local recurrences.
- 83.3% of patients had good/excellent cosmetic results.
- 100% of patients would recommend MammoSite targeted radiation therapy to a friend or family member.
- 100% of patients would use MammoSite targeted radiation therapy if they had to do it over.
The safety and effectiveness of the MammoSite® radiation therapy system (RTS), MammmoSite® ML radiation therapy system and the Contura® applicator as a replacement for whole breast irradiation in the treatment of breast cancer has not been established.
More information can be found here
Loading...
Poland: Yes, We Will Use J&J Vaccine!
The Polish government has announced that 120 000 units of Johnson&Johnson... Read more
Advantech Connect Online Partner Conference to Promote Edge-to-Cloud Partnerships & AIoT Solutions
Advantech , a leading provider of advanced IoT intelligence systems,... Read more
Anticoagulation Therapy in Patients With COVID-19
No therapy is currently recommended for COVID-19. Some data from registries... Read more
Break Through Your Workflow Barriers With 3DQuorum™. Our Highest Resolution 3D™ Imaging, Faster
At Hologic , we understand the importance of reducing imaging interpretati Read more
Accelerate Detection With The 3DQuorum™, The Ultimate Breast Tomosynthesis Technology
Hologic is pleased to introduce 3DQuorum Imaging Technology Read more
Hologic Announces Commitment to Tackling Breast Cancer Screening Disparities for Black Women
Initiative includes awareness campaign featuring Mary J. Blige and funding... Read more
JOIN OUR MANAGEMENT COMMUNITY
Advantech Connect Online Partner Conference to Promote Edge-to-Cloud Partnerships & AIoT Solutions
Advantech , a leading provider of advanced IoT intelligence systems,... Read more
Masimo Announces FDA Clearance of Radius PCG™ for Root® Patient Monitoring & Connectivity Platform
Masimo (NASDAQ: MASI) announced today that Radius PCG™, a portable real- Read more
Hologic Receives Gallup Exceptional Workplace Award
Hologic, Inc. , a global leader in women's health, has been named a winner... Read more
Break Through Your Workflow Barriers With 3DQuorum™. Our Highest Resolution 3D™ Imaging, Faster
At Hologic , we understand the importance of reducing imaging interpretati Read more
AGFA-DELL Partnership: Hardware Solutions for Storage Boost Clinician Efficiency
To provide our Enterprise Imaging customers with powerful hardware solutions... Read more
1,000+ Peer Reviewed Publications Confirm Trust In Most Popular Finger Blood Pressure Method
We are happy to announce that to date our CNAP® technology for Read more
New Fluoroscopy System From Siemens Healthineers Combines Industry-Leading Fluoroscopy & Radiography
Journées Francophones de Radiologie Diagnostique & Interventionnelle... Read more
Patient’s Moment Has Arrived
It is clear that the COVID-19 crisis has been a boost in the digitisation Read more
New AMA President: Dr Susan Bailey
The 175th president of the American Medical Association (AMA),... Read more
Oliver Reichardt, RCR‘s New Chief Executive
As of May 4, Oliver Reichardt is new Chief Executive of t he... Read more
Dr. Sebastian Krolop appointed Chief Operating & Strategy Officer of HIMSS
Dr. Sebastian Krolop, M.D., Ph.D., M. Sc. has recently been appointed the... Read more
Dr. Paul Wischmeyer earns prestigious FASPEN award
The American Society for Parenteral and Enteral Nutrition (ASPEN) has... Read more
John Ormiston Awarded the EuroPCR 2017 Ethica Award
The 2017 Ethica Award, the highest honour of the European cardiovascular... Read more
Gamma Medica Bolsters Executive Team to Support Fight Against Breast Cancer
Gamma Medica, a leader in molecular breast imaging (MBI) technology, announced... Read more
JOIN OUR MANAGEMENT COMMUNITY
JOIN OUR MANAGEMENT COMMUNITY